GDTC vs. ONCT, CPIX, BIOR, BFRG, ENLV, LUMO, SYBX, SNSE, UBX, and MEIP
Should you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include Oncternal Therapeutics (ONCT), Cumberland Pharmaceuticals (CPIX), Biora Therapeutics (BIOR), Bullfrog AI (BFRG), Enlivex Therapeutics (ENLV), Lumos Pharma (LUMO), Synlogic (SYBX), Sensei Biotherapeutics (SNSE), Unity Biotechnology (UBX), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical preparations" industry.
CytoMed Therapeutics (NASDAQ:GDTC) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, community ranking, risk and institutional ownership.
CytoMed Therapeutics has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -5,029.17%. CytoMed Therapeutics' return on equity of 0.00% beat Oncternal Therapeutics' return on equity.
0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 16.1% of Oncternal Therapeutics shares are owned by institutional investors. 8.0% of Oncternal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Oncternal Therapeutics received 26 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CytoMed Therapeutics an outperform vote while only 31.82% of users gave Oncternal Therapeutics an outperform vote.
CytoMed Therapeutics has higher earnings, but lower revenue than Oncternal Therapeutics.
In the previous week, Oncternal Therapeutics had 2 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 3 mentions for Oncternal Therapeutics and 1 mentions for CytoMed Therapeutics. Oncternal Therapeutics' average media sentiment score of 0.21 beat CytoMed Therapeutics' score of -1.00 indicating that Oncternal Therapeutics is being referred to more favorably in the news media.
CytoMed Therapeutics currently has a consensus target price of $5.00, indicating a potential upside of 138.10%. Oncternal Therapeutics has a consensus target price of $31.33, indicating a potential upside of 277.97%. Given Oncternal Therapeutics' higher probable upside, analysts clearly believe Oncternal Therapeutics is more favorable than CytoMed Therapeutics.
Summary
Oncternal Therapeutics beats CytoMed Therapeutics on 8 of the 14 factors compared between the two stocks.
Get CytoMed Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GDTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CytoMed Therapeutics Competitors List
Related Companies and Tools
